Hormone withdrawal-associated symptoms: Comparison of oestradiol valerate/dienogest versus ethinylestradiol/norgestimate

REFERENCES

• Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000;95:261–6.
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Frith A, Ellis J, et al. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology 2006;67:2154–8.
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Frith A, Ellis J, et al. Prevention of menstrual attacks of migraine: A double-blind placebo- controlled crossover study. Neurology 2006;67:2159–63.
   PubMed Web of Science ®Google Scholar
• MacGregor EA. Oestrogen and attacks of migraine with and without aura. Lancet Neurol 2004;3:354–61.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Nappi G. Neuroendocrine aspects of migraine in women. Gynecol Endocrinol 2012;28(Suppl. 1):37–41.
   PubMedGoogle Scholar
• Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders, 2nd edn. Cephalalgia 2004;24 (Suppl. 1):9–160.
   Google Scholar
• Allais G, Castagnoli Gabellari I, De Lorenzo C, et al. Oral contraceptives in migraine therapy. Neurol Sci 2011;32 (Suppl. 1):S135–9.
   PubMedGoogle Scholar
• Allais G, Gabellari IC, Airola G, et al. Headache induced by the use of combined oral contraceptives. Neurol Sci 2009;30 (Suppl. 1):S15–7.
   PubMedGoogle Scholar
• Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 1996;54: 71–7.
   PubMed Web of Science ®Google Scholar
• Sulak P, Willis S, Kuehl T, et al. Headaches and oral contraceptives: Impact of eliminating the standard 7-day placebo interval. Headache 2007;47:27–37.
   PubMed Web of Science ®Google Scholar
• Sulak PJ, Cressman BE, Waldrop E, et al. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 1997; 89:179–83.
   PubMed Web of Science ®Google Scholar
• Zeun S, Lu M, Uddin A, et al. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care 2009;14:221–32.
   PubMed Web of Science ®Google Scholar
• Merki-Feld G, Macias G, Parke S, et al. Hormone withdrawal-associated symptoms (headache and pelvic pain) in women taking combined oral contraceptives: Comparison of oestradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Eur J Contracept Reprod Health Care 2012;17 (Suppl. 1):S100.
   Google Scholar
• Loder EW, Buse DC, Golub JR. Headache as a side effect of combination estrogen-progestin oral contraceptives: A systematic review. Am J Obstet Gynecol 2005;193:636–49.
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Chia H, Vohrah RC, et al. Migraine and menstruation: A pilot study. Cephalalgia 1990;10: 305–10.
   PubMed Web of Science ®Google Scholar
• Johannes CB, Linet MS, Stewart WF, et al. Relationship of headache to phase of the menstrual cycle among young women: A daily diary study. Neurology 1995;45: 1076–82.
   PubMed Web of Science ®Google Scholar
• MacGregor A. Migraine associated with menstruation. Funct Neurol 2000;15(Suppl. 3):143–53.
   PubMed Web of Science ®Google Scholar
• Martelletti P, Farinelli I, Coloprisco G, et al. Role of NSAIDs in acute treatment of headache. Drug Dev Res 2007;68:276–81.
   Web of Science ®Google Scholar
• Lefebvre G, Pinsonneault O, Antao V, et al. Primary dysmenorrhea consensus guideline. J Obstet Gynaecol Can 2005;27:1117–46.
   PubMedGoogle Scholar
• Klipping C, Duijkers I, Trummer D, et al. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008; 78:16–25.
   PubMed Web of Science ®Google Scholar
• Ruan X, Seeger H, Mueck AO. The pharmacology of dienogest. Maturitas 2012;71:337–44.
   PubMed Web of Science ®Google Scholar
• Ortho Tri-Cyclen® Lo Full Prescribing Information. Accessed 7 February 2013 from: http://www.myortho360.com/sites/default/files/assets/Tri-Cyclen_Lo_PI.pdf#zoom=100
   Google Scholar
• Kuhl H. Pharmacology of estrogens and gestagens. In: Fischl FH, ed. Menopause – Andropause: Hormone replacement therapy through the ages: New cognition and therapy concepts. Gablitz, Germany: Krause & Pachernegg GmbH 2001:33–50.
   Google Scholar
• Jensen MP, Karoly P. Self-report scales and procedures for assessing pain in adults. In: Turk DC & Melzack R, eds. Handbook of pain assessment. New York: Guilford Press 2001:15–34.
   Google Scholar
• Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: A reanalysis of two clinical trials of postoperative pain. J Pain 2003;4:407–14.
   PubMed Web of Science ®Google Scholar
• Rowbotham MC. What is a “clinically meaningful” reduction in pain?. Pain 2001;94:131–2.
   PubMed Web of Science ®Google Scholar
• Todd KH, Funk KG, Funk JP, et al. Clinical significance of reported changes in pain severity. Ann Emerg Med 1996;27:485–9.
   PubMed Web of Science ®Google Scholar
• Moos R. Menstrual Distress Questionnaire (MDQ) – The standard method for measuring cyclical perimenstrual symptoms, 4th edn. Accessed 5 July 2012 from: http://www.mindgarden.com/products/mdq.htm
   Google Scholar
• Busner J, Targum SD. The clinical global impressions scale: Applying a research tool in clinical practice. Psychiatry 2007;4:28–37.
   PubMedGoogle Scholar
• de Boer AG, van Lanschot JJ, Stalmeier PF, et al. Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life?. Qual Life Res 2004;13:311–20.
   PubMed Web of Science ®Google Scholar